Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last kr3.27 DKK
Change Today +0.04 / 1.24%
Volume 11.7K
NEUR On Other Exchanges
Symbol
Exchange
Copenhagen
OTC US
As of 10:59 AM 05/6/15 All times are local (Market data is delayed by at least 15 minutes).

neurosearch a/s (NEUR) Snapshot

Open
kr3.23
Previous Close
kr3.23
Day High
kr3.27
Day Low
kr3.23
52 Week High
05/26/14 - kr3.62
52 Week Low
12/30/14 - kr2.45
Market Cap
80.3M
Average Volume 10 Days
42.9K
EPS TTM
kr-0.56
Shares Outstanding
24.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NEUROSEARCH A/S (NEUR)

Related News

No related news articles were found.

neurosearch a/s (NEUR) Related Businessweek News

No Related Businessweek News Found

neurosearch a/s (NEUR) Details

NeuroSearch A/S is engaged in the research and development of drug candidates. The company’s product pipeline comprises Tesofensine, a monoamine reuptake inhibitor that has completed Phase II clinical trials for obesity; Seridopidine and Ordopidine that are dopaminergic stabilizers, which have completed Phase I clinical trials for CNS disease; and NS2359 that has completed Phase I clinical trials. Its drug candidates affect the central nervous system and are directed towards indications, such as motor disorders, obesity, and drug abuse. NeuroSearch A/S is based in Hellerup, Denmark.

2 Employees
Last Reported Date: 02/27/15

neurosearch a/s (NEUR) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

neurosearch a/s (NEUR) Key Developments

NeuroSearch A/S Announces Earnings Results for the Quarter Ended March 31, 2015; Provides Earnings Guidance for the Year 2015

NeuroSearch A/S announced earnings results for the quarter ended March 31, 2015. For the quarter, the company posted an operating loss of DKK 2 million compared to DKK 2 million a year ago. Loss after tax of DKK 4 million compared to a loss of DKK 2 million a year ago. In 2015, the company expects an operating loss in the range of DKK 7 million to DKK 9 million.

Neurosearch A/S Proposes Amendments to Articles of Association

Neurosearch A/S will consider proposes to amend Article 5 of the Articles of Association so that any new shares to be issued by the company shall be issued in the name of the holder. The Board of Directors proposes to extend the Board of Directors' authorisation to increase the share capital of the company until 15 April 2020 and, thus, amending Article 4 of the Articles of Association.

Neurosearch A/S Reports Audited Consolidated Earnings Results for the Year 2014; Provides Earnings Guidance for the Year 2015

NeuroSearch A/S reported audited consolidated earnings results for the year 2014. For the year, the company posted an operating loss on continuing operations of DKK 13 million compared to DKK 10 million, which was on a level with the Company's previously announced expectations of an operating loss of DKK 15 million. Posted a loss after tax on continuing operations was DKK 9 million compared to DKK 3 million a year ago. Consolidated loss was DKK 8 million compared to a profit of DKK 12 million a year ago. Diluted loss per share was DKK 0.32 compared to diluted earnings per share of DKK 0.50 a year ago. Operating loss was DKK 13,266,000 compared to DKK 9,615,000 a year ago. Diluted loss per share continuing operations of DKK 0.38 compared to DKK 0.13 a year ago. Cash out flow from operating activities was DKK 8,143,000 compared to DKK 47,103,000 a year ago. For 2015, the company expects an operating loss in the range of DKK 7-9 million. The outlook does not include any income from the possible sale of Company assets, potential income from the Company's agreements with Teva, Saniona or others, and neither does the outlook take into account a potential reversal of the provision of DKK 5 million made to cover the fine the Company has been ordered to pay.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NEUR:DC kr3.27 DKK +0.04

NEUR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NEUR.
View Industry Companies
 

Industry Analysis

NEUR

Industry Average

Valuation NEUR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 0.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEUROSEARCH A/S, please visit www.neurosearch.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.